Erythropoietin and its receptors in the brainstem of adults with fatal falciparum malaria

Malaria Journal

Volumn 8, Issue 1, 2009, Pages

  Medana, Isabelle M ^a   Day, Nicholas Pj ^b,c   Hien, Tran Tinh ^d   White, Nicholas J ^b,c   Turner, Gareth Dh ^a,b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c MAHIDOL OXFORD TROPICAL MEDICINE RESEARCH UNIT   (Thailand)

^d UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD131 ANTIGEN; ERYTHROPOIETIN; ERYTHROPOIETIN RECEPTOR; LACTIC ACID; CSF2RB PROTEIN, HUMAN;

ACUTE KIDNEY FAILURE; ADULT; ARTERIAL OXYGEN SATURATION; ARTICLE; BLEEDING; BLOOD VESSEL INJURY; BLOOD VESSEL PERMEABILITY; BRAIN STEM; CLINICAL ARTICLE; CONTROLLED STUDY; DYING; FEMALE; GLIA; HUMAN; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALARIA FALCIPARUM; MALE; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; UNITED KINGDOM; AGED; BIOSYNTHESIS; BRAIN ISCHEMIA; CASE CONTROL STUDY; METABOLISM; MIDDLE AGED; PATHOLOGY; PLASMODIUM FALCIPARUM; VIET NAM;

ADULT; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; BRAIN STEM; CASE-CONTROL STUDIES; CYTOKINE RECEPTOR COMMON BETA SUBUNIT; ERYTHROPOIETIN; FEMALE; GREAT BRITAIN; HUMANS; IMMUNOHISTOCHEMISTRY; MALARIA, FALCIPARUM; MALE; MIDDLE AGED; PLASMODIUM FALCIPARUM; RECEPTORS, ERYTHROPOIETIN; VIETNAM; YOUNG ADULT;

EID: 72449177991     PISSN: None     EISSN: 14752875     Source Type: Journal    
DOI: 10.1186/1475-2875-8-261     Document Type: Article

References (52)

1. Hematopoietic cytokines - on the verge of conquering neurology. L Tonges JC Schlachetzki JH Weishaupt M Bahr, Curr Mol Med 2007 7 157 170 10.2174/156652407780059186 17346168
2. Neuronal damage after moderate hypoxia and erythropoietin. A Weber M Dzietko M Berns U Felderhoff-Mueser U Heinemann RF Maier M Obladen C Ikonomidou C Buhrer, Neurobiol Dis 2005 20 594 600 10.1016/j.nbd.2005.04.016 15935685
3. Erythropoietin and ischemic conditioning - why two good things may be bad. C Buhrer U Felderhoff-Mueser S Wellmann, Acta Paediatr 2007 96 787 789 10.1111/j.1651-2227.2007.00335.x 17537001
4. The relationship between age and the manifestations of and mortality associated with severe malaria. AM Dondorp SJ Lee MA Faiz S Mishra R Price E Tjitra M Than Y Htut S Mohanty EB Yunus, et al. Clin Infect Dis 2008 47 151 157 10.1086/589287 18533842
5. Can erythropoietin be used to prevent brain damage in cerebral malaria? C Casals-Pascual R Idro S Picot DJ Roberts CR Newton, Trends Parasitol 2009 25 30 36 10.1016/j.pt.2008.10.002 19008152
6. High levels of erythropoietin are associated with protection against neurological sequelae in African children with cerebral malaria. C Casals-Pascual R Idro N Gicheru S Gwer B Kitsao E Gitau R Mwakesi DJ Roberts CR Newton, Proc Natl Acad Sci USA 2008 105 2634 2639 10.1073/pnas.0709715105 18263734
7. Artesunate-erythropoietin combination for murine cerebral malaria treatment. AL Bienvenu J Ferrandiz K Kaiser C Latour S Picot, Acta Trop 2008 106 104 108 10.1016/j.actatropica.2008.02.001 18359468
8. Recombinant human erythropoietin prevents the death of mice during cerebral malaria. K Kaiser A Texier J Ferrandiz A Buguet A Meiller C Latour F Peyron R Cespuglio S Picot, J Infect Dis 2006 193 987 995 10.1086/500844 16518761
9. Recombinant human erythropoietin increases survival and reduces neuronal apoptosis in a murine model of cerebral malaria. L Wiese C Hempel M Penkowa N Kirkby JA Kurtzhals, Malar J 2008 7 3 10.1186/1475-2875-7-3 18179698
10. ClinicalTrials.gov. http://www.ClinicalTrials.gov
11. Safety of epoietin beta-quinine drug combination in children with cerebral malaria in Mali. S Picot AL Bienvenu S Konate S Sissoko A Barry E Diarra K Bamba A Djimde OK Doumbo, Malar J 2009 8 169 10.1186/1475-2875-8-169 19630971
12. Brain erythropoietin receptor expression in Alzheimer disease and mild cognitive impairment. MI Assaraf Z Diaz A Liberman WH Miller Jr Z Arvanitakis Y Li DA Bennett HM Schipper, J Neuropathol Exp Neurol 2007 66 389 398 10.1097/nen.0b013e3180517b28 17483696
13. Increased expression of erythropoietin receptor on blood vessels in the human epileptogenic hippocampus with sclerosis. T Eid ML Brines A Cerami DD Spencer JH Kim JS Schweitzer OP Ottersen NC de Lanerolle, J Neuropathol Exp Neurol 2004 63 73 83 14748563
14. Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain. AL Siren F Knerlich W Poser CH Gleiter W Bruck H Ehrenreich, Acta Neuropathol 2001 101 271 276 11307627
15. The transcriptional activator hypoxia inducible factor 2 (HIF-2/EPAS-1) regulates the oxygen-dependent expression of erythropoietin in cortical astrocytes. JC Chavez O Baranova J Lin P Pichiule, J Neurosci 2006 26 9471 9481 10.1523/JNEUROSCI.2838-06.2006 16971531
16. Production and processing of erythropoietin receptor transcripts in brain. K Chin X Yu B Beleslin-Cokic C Liu K Shen HW Mohrenweiser CT Noguchi, Brain Res Mol Brain Res 2000 81 29 42 10.1016/S0169-328X(00)00157-1 11000476
17. Regulation of the erythropoietin gene. BL Ebert HF Bunn, Blood 1999 94 1864 1877 10477715
18. Biology of erythropoietin. W Jelkmann, Clin Investig 1994 72 3 10 7950169
19. Human cerebral malaria and the blood-brain barrier. IM Medana GD Turner, Int J Parasitol 2006 36 555 568 16616145 10.1016/j.ijpara.2006.02.004 (Pubitemid 43674514)
20. Erythropoietin protects the in vitro blood-brain barrier against VEGF-induced permeability. OM Martinez-Estrada E Rodriguez-Millan E Gonzalez-De Vicente M Reina S Vilaro M Fabre, Eur J Neurosci 2003 18 2538 2544 10.1046/j.1460-9568.2003.02987.x 14622154
21. Amelioration of spinal cord compressive injury by pharmacological preconditioning with erythropoietin and a nonerythropoietic erythropoietin derivative. G Grasso A Sfacteria S Erbayraktar M Passalacqua F Meli N Gokmen O Yilmaz D La Torre M Buemi DG Iacopino, et al. J Neurosurg Spine 2006 4 310 318 10.3171/spi.2006.4.4.310 16619678
22. Nonhematopoietic erythropoietin derivatives prevent motoneuron degeneration in vitro and in vivo. T Mennini M De Paola P Bigini C Mastrotto E Fumagalli S Barbera M Mengozzi B Viviani E Corsini M Marinovich, et al. Mol Med 2006 12 153 160 10.2119/2006-00045.Mennini 17088947
23. Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Y Wang ZG Zhang K Rhodes M Renzi RL Zhang A Kapke M Lu C Pool G Heavner M Chopp, Br J Pharmacol 2007 151 1377 1384 10.1038/sj.bjp.0707285 17603558
24. Quantitative image analysis of the chromatolysis in rat facial and hypoglossal motoneurons following axotomy with and without reinnervation. O Guntinas-Lichius WF Neiss E Schulte E Stennert, Cell Tissue Res 1996 286 537 541 10.1007/s004410050723 8929356 (Pubitemid 26418062)
25. Neuropathological assessment of artemether-treated severe malaria. TT Hien GD Turner NT Mai NH Phu D Bethell WF Blakemore JB Cavanagh A Dayan I Medana RO Weller, et al. Lancet 2003 362 295 296 10.1016/S0140-6736(03)13974-8 12892962
26. Axonal injury in cerebral malaria. IM Medana NP Day TT Hien NT Mai D Bethell NH Phu J Farrar MM Esiri NJ White GD Turner, Am J Pathol 2002 160 655 666 11839586
27. Role of erythropoietin in the brain. CT Noguchi P Asavaritikrai R Teng Y Jia, Crit Rev Oncol Hematol 2007 64 159 171 10.1016/j.critrevonc.2007.03.001 17482474
28. Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor. M Brines G Grasso F Fiordaliso A Sfacteria P Ghezzi M Fratelli R Latini QW Xie J Smart CJ Su-Rick, et al. Proc Natl Acad Sci USA 2004 101 14907 14912 10.1073/pnas.0406491101 15456912
29. A controlled trial of artemether or quinine in Vietnamese adults with severe falciparum malaria. TT Hien NP Day HP Nguyen TH Nguyen TH Tran PL Pham XS Dinh VC Ly V Ha D Waller, et al. N Engl J Med 1996 335 76 83 10.1056/NEJM199607113350202 8649493
30. Severe falciparum malaria. World Health Organization CDC, Trans R Soc Trop Med Hyg 2000 94 Suppl 1 1 90 10.1016/S0035-9203(00)90300-6 11103309
31. Cellular stress and injury responses in the brains of adult Vietnamese patients with fatal Plasmodium falciparum malaria. IM Medana NT Mai NP Day TT Hien D Bethell NH Phu J Farrar NJ White GD Turner, Neuropathol Appl Neurobiol 2001 27 421 433 10.1046/j.0305-1846.2001.00360.x 11903925
32. Erythropoietin in cerebrospinal fluid: age-related reference values and relevance in neurological disease. K Widl J Brettschneider D Schattauer S Sussmuth R Huber AC Ludolph H Tumani, Neurochem Res 2007 32 1163 1168 10.1007/s11064-007-9286-0 17401663
33. Erythropoietin receptor expression is concordant with erythropoietin but not with common beta chain expression in the rat brain throughout the life span. PE Sanchez FP Navarro RP Fares J Nadam B Georges C Moulin M Le Cavorsin C Bonnet P Ryvlin A Belmeguenai, et al. J Comp Neurol 2009 514 403 414 10.1002/cne.22020 19330822
34. RA Fishman, Cerebrospinal fluid in diseases of the nervous system Philadelphia: W.B. Saunders Company 2 1992
35. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. ML Brines P Ghezzi S Keenan D Agnello NC de Lanerolle C Cerami LM Itri A Cerami, Proc Natl Acad Sci USA 2000 97 10526 10531 10.1073/pnas.97.19.10526 10984541
36. Carbamylated erythropoietin ameliorates the metabolic stress induced in vivo by severe chronic hypoxia. M Fantacci P Bianciardi A Caretti TR Coleman A Cerami M Brines M Samaja, Proc Natl Acad Sci USA 2006 103 17531 17536 10.1073/pnas.0608814103 17090665
37. Histological and functional outcomes after traumatic brain injury in mice null for the erythropoietin receptor in the central nervous system. Y Xiong A Mahmood D Lu C Qu H Kazmi A Goussev ZG Zhang CT Noguchi T Schallert M Chopp, Brain Res 2008 1230 247 257 10.1016/j.brainres.2008.06.127 18657521
38. Neuroprotection by erythropoietin administration after experimental traumatic brain injury. G Grasso A Sfacteria F Meli V Fodale M Buemi DG Iacopino, Brain Res 2007 1182 99 105 10.1016/j.brainres.2007.08.078 17935704
39. Erythropoietin protects from post-traumatic edema in the rat brain. O Verdonck H Lahrech G Francony O Carle R Farion Y Van de Looij C Remy C Segebarth JF Payen, J Cereb Blood Flow Metab 2007 27 1369 1376 10.1038/sj.jcbfm.9600443 17264861
40. Derivatives of erythropoietin that are tissue protective but not erythropoietic. M Leist P Ghezzi G Grasso R Bianchi P Villa M Fratelli C Savino M Bianchi J Nielsen J Gerwien, et al. Science 2004 305 239 242 10.1126/science.1098313 15247477
41. A "classical" homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. M Um AW Gross HF Lodish, Cell Signal 2007 19 634 645 10.1016/j.cellsig.2006.08.014 17045782
42. Functional cross-talk between cytokine receptors revealed by activating mutations in the extracellular domain of the beta-subunit of the GM-CSF receptor. TJ Blake BJ Jenkins RJ D'Andrea TJ Gonda, J Leukoc Biol 2002 72 1246 1255 12488507
43. The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor. PT Jubinsky OI Krijanovski DG Nathan J Tavernier CA Sieff, Blood 1997 90 1867 1873 9292519
44. Axonal and astrocyte injury markers in the cerebrospinal fluid of Kenyan children with severe malaria. IM Medana R Idro CR Newton, J Neurol Sci 2007 258 93 98 10.1016/j.jns.2007.03.005 17459417
45. Erythropoietin is neuroprotective, improves functional recovery, and reduces neuronal apoptosis and inflammation in a rodent model of experimental closed head injury. I Yatsiv N Grigoriadis C Simeonidou PF Stahel OI Schmidt AG Alexandrovitch J Tsenter E Shohami, Faseb J 2005 19 1701 1703 16099948
46. Does the neuroprotective agent erythropoietin amplify diffuse axonal injury in its early stages? RS Tubbs MM Shoja M Jamshidi G Shokouhi, Med Hypotheses 2007 69 1385 1386 10.1016/j.mehy.2007.03.002 17449190
47. Cerebral calpain in fatal falciparum malaria. IM Medana NP Day TT Hien NT Mai D Bethell NH Phu GD Turner J Farrar NJ White MM Esiri, Neuropathol Appl Neurobiol 2007 33 179 192 10.1111/j.1365-2990.2006.00777.x 17359359
48. Hsp70 regulates erythropoiesis by preventing caspase-3-mediated cleavage of GATA-1. JA Ribeil Y Zermati J Vandekerckhove S Cathelin J Kersual M Dussiot S Coulon IC Moura A Zeuner T Kirkegaard-Sorensen, et al. Nature 2007 445 102 105 10.1038/nature05378 17167422
49. Preconditioning with erythropoietin protects against subsequent ischemia-reperfusion injury in rat kidney. CW Yang C Li JY Jung SJ Shin BS Choi SW Lim BK Sun YS Kim J Kim YS Chang BK Bang, Faseb J 2003 17 1754 1755 10.1096/fj.02-0654rev 12958199
50. An ultrastructural study of the brain in fatal Plasmodium falciparum malaria. E Pongponratn GD Turner NP Day NH Phu JA Simpson K Stepniewska NT Mai P Viriyavejakul S Looareesuwan TT Hien, et al. Am J Trop Med Hyg 2003 69 345 359 14640492
51. Angiopoietin-2 is associated with decreased endothelial nitric oxide and poor clinical outcome in severe falciparum malaria. TW Yeo DA Lampah R Gitawati E Tjitra E Kenangalem K Piera RN Price SB Duffull DS Celermajer NM Anstey, Proc Natl Acad Sci USA 2008 105 17097 17102 10.1073/pnas.0805782105 18957536
52. Erythropoietin and hypoxia stimulate erythropoietin receptor and nitric oxide production by endothelial cells. BB Beleslin-Cokic VP Cokic X Yu BB Weksler AN Schechter CT Noguchi, Blood 2004 104 2073 2080 10.1182/blood-2004-02- 0744 15205261